Search research articles
Contact Us
Filters
Showing results (241-250 of 259) with videos related to
Page
of 26
Sort By:
AIDS (London, England)
|
December 18, 2018
The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM
Ian McGowan, Timothy Wilkin, Raphael J Landovitz, et al.
Cancer Causes & Control : CCC
|
November 3, 2016
The association of medication use with clearance or persistence of oral HPV infection
Jennifer O Lam, Elizabeth A Sugar, Ross D Cranston, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 10, 2021
Xpert HPV as a Screening Tool for Anal Histologic High-Grade Squamous Intraepithelial Lesions in Women Living With HIV
Grant B Ellsworth, Elizabeth A Stier, Elizabeth Y Chiao, et al.
Elife
|
February 4, 2015
Mucosal effects of tenofovir 1% gel
Florian Hladik, Adam Burgener, Lamar Ballweber, et al.
Elife
|
March 25, 2015
Correction: Musosal effects for tenofovir 1% gel
Florian Hladik, Adam Burgener, Lamar Ballweber, et al.
The Lancet. HIV
|
September 24, 2016
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment
Ian McGowan, Charlene S Dezzutti, Aaron Siegel, et al.
AIDS and Behavior
|
November 10, 2017
Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men
Alex Carballo-Diéguez, Rebecca Giguere, Curtis Dolezal, et al.
Plos One
|
May 6, 2015
A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study)
Ian Mcgowan, Ross D Cranston, Kathryn Duffill, et al.
AIDS (London, England)
|
April 8, 2021
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis
Rogers Sekabira, Ian McGowan, Krista Yuhas, et al.
AIDS Research and Human Retroviruses
|
August 13, 2021
A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study)
Ian M McGowan, Sylvain Chawki, Craig W Hendrix, et al.
Page
of 26
Search research articles
Search
Showing results (241-250 of 259) with videos related to
Sort By:
Page
of 26
AIDS (London, England)
|
December 18, 2018
The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM
Ian McGowan, Timothy Wilkin, Raphael J Landovitz, et al.
Cancer Causes & Control : CCC
|
November 3, 2016
The association of medication use with clearance or persistence of oral HPV infection
Jennifer O Lam, Elizabeth A Sugar, Ross D Cranston, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 10, 2021
Xpert HPV as a Screening Tool for Anal Histologic High-Grade Squamous Intraepithelial Lesions in Women Living With HIV
Grant B Ellsworth, Elizabeth A Stier, Elizabeth Y Chiao, et al.
Elife
|
February 4, 2015
Mucosal effects of tenofovir 1% gel
Florian Hladik, Adam Burgener, Lamar Ballweber, et al.
Elife
|
March 25, 2015
Correction: Musosal effects for tenofovir 1% gel
Florian Hladik, Adam Burgener, Lamar Ballweber, et al.
The Lancet. HIV
|
September 24, 2016
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment
Ian McGowan, Charlene S Dezzutti, Aaron Siegel, et al.
AIDS and Behavior
|
November 10, 2017
Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men
Alex Carballo-Diéguez, Rebecca Giguere, Curtis Dolezal, et al.
Plos One
|
May 6, 2015
A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study)
Ian Mcgowan, Ross D Cranston, Kathryn Duffill, et al.
AIDS (London, England)
|
April 8, 2021
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis
Rogers Sekabira, Ian McGowan, Krista Yuhas, et al.
AIDS Research and Human Retroviruses
|
August 13, 2021
A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study)
Ian M McGowan, Sylvain Chawki, Craig W Hendrix, et al.
Page
of 26